Teva Canada Ltd v Novartis AG / imatinib 2013 FC 141, Snider J
GLEEVEC / imatinib mesylate / 2,093,203
[164] Sound prediction is not a free-standing statutory requirement. Rather, it is a way of showing that an invention is useful when the invention has not been directly demonstrated to work. Its introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents.
This is technically and historically correct, but it does not mean that patentees have no cause for complaint. Sound prediction originated as an aid to patentees, but some developments have been very problematic. These stem from a pregnant passage in Wellcome / AZT 2002 SCC 77 [70], that said that to support sound prediction, in addition to a factual basis and a sound line of reasoning:
there must be proper disclosure. . . . In this sort of case, however, the sound prediction is to some extent the quid pro quo the applicant offers in exchange for the patent monopoly. Precise disclosure requirements in this regard do not arise for decision in this case because both the underlying facts (the test data) and the line of reasoning (the chain terminator effect) were in fact disclosed, and disclosure in this respect did not become an issue between the parties. I therefore say no more about it.
While these remarks are expressly obiter, they suggest that when utility is based on sound prediction, there may be a requirement that the facts and line of reasoning be disclosed in the patent itself. This suggestion was taken up by Hughes J in Lilly / raloxifene 2008 FC 142 [164] and affirmed by the FCA 2009 FCA 97 [15], holding that the factual basis for sound disclosure be provided in the patent itself: see my article “Must the Factual Basis for Sound Prediction Be Disclosed in the Patent?” (2012) 28 CIPR 39, draft version here. Furthermore, in its Latanoprost decision, 2011 FCA 236, the FCA strongly implied that the line of reasoning must also be disclosed in the patent.
In her imatinib decision, Snider J held that the utility of some use claims and some genus claims was established based on sound prediction. Consequently her decisions navigates the shoals of these heightened disclosure requirements.